Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT02338245
- Locations
- 🇵🇭
Philippines, Dasmarinas, Philippines
🇸🇬Singapore, Singapore, Singapore
🇦🇺Australia, Western Australia, Australia
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 318
- Registration Number
- NCT02335411
Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 710
- Registration Number
- NCT02316535
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
- Conditions
- Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 645
- Registration Number
- NCT02314117
- Locations
- 🇺🇸
UT Southwestern Med Ctr, Dallas, Texas, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
- Conditions
- Pancreatic Neoplasms
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 107
- Registration Number
- NCT02301143
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸Tufts - New England Medical Center, Boston, Massachusetts, United States
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 44
- Registration Number
- NCT02297230
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02294786
- Locations
- 🇬🇧
Novartis Investigative Site, Romford, United Kingdom
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- Interventions
- Drug: FOLFOX induction regimenDrug: Fluoropyrimidine (5-FU/LV or capecitabine)Drug: CetuximabDrug: TrastuzumabDrug: BevacizumabDrug: PertuzumabDrug: VemurafenibDrug: AtezolizumabDrug: CobimetinibDrug: 5-FU/LVDrug: Capecitabine
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1044
- Registration Number
- NCT02291289
- Locations
- 🇦🇷
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología, Buenos Aires, Argentina
🇧🇪Institut Jules Bordet X, Brussels, Belgium
🇧🇪Hospital Erasme, Bruxelles, Belgium
Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 184
- Registration Number
- NCT02289547
- Locations
- 🇰🇷
St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Incheon St. Mary's Hospital, Incheon, Korea, Republic of
🇰🇷St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.